Potential peptide to treat multiple sclerosis passes toxicology test
A peptide that could treat multiple sclerosis caused no neurotoxicity or cardiotoxic effects in zebrafish, a study has shown.
List view / Grid view
A peptide that could treat multiple sclerosis caused no neurotoxicity or cardiotoxic effects in zebrafish, a study has shown.
A team has developed a novel inhibitor that blocks a protein in cancer cells, making drug-resistant tumours respond to chemotherapy.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
Researchers have discovered the the compound triptonide is safe, effective and reversible as a male contraceptive in animal models.
Using high-throughput screening techniques, researchers have identified two families of active substances that block SARS-CoV-2 replication.
4 March 2021 | By Eurofins Discovery
Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.
As laboratories face the challenge of screening many samples for SARS-CoV-2, lab managers have turned to the use of automation to address key concerns.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Phenotypic profiling identifies biomarkers and mechanisms of toxicity.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
Researchers have shown that adding a polymer to glutamate-oxaloacetate transaminase means the molecule can treat stroke for up to six days in rats.